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Abstract 
 
The 26S proteasome is a protein complex that plays a critical role in the degradation of 
cellular proteins including transcription factors, cyclins, and other proteins required for cell cycle 
progression in normal and malignant cells. Bortezomib (PS-341, Velcade) is a specific and 
selective inhibitor of the 26S proteasome that has cytotoxic activity against tumor cells.  
Treatment with this compound has been shown to induce apoptosis in malignant cells.  
Interferon-alpha (IFN-α) is an immunostimulatory cytokine that is known to inhibit proliferation 
and to promote apoptosis in tumor cells.  Apoptosis of human melanoma cells was evaluated 
following treatment with PBS, bortezomib (10nM), IFN-α (104 U/mL), or both agents combined 
by Annexin V/ propidium iodide (PI) staining and demonstrated that cell death was synergistic in 
nature.  The pro-apoptotic activity of this treatment combination was evident in multiple 
malignant melanoma cell lines (1259 MEL, 18105 MEL, A375) indicating that this effect was 
not cell line specific.  Cell death induced by bortezomib and IFN-α was associated with cleavage 
of caspase proteins (caspase-3, -7) and poly ADP-ribose polymerase (PARP).  Interestingly, 
levels of the cyclin dependent kinase inhibitor, p21, were increased slightly following treatment 
with bortezomib plus IFN-α.  Levels of the pro-survival mitochondrial membrane protein Bcl-2 
were decreased in a synergistic manner following treatment of human melanoma cells with 
bortezomib and IFN-α combined.  Real-Time PCR analysis demonstrated that pre-treatment of 
melanoma cells with bortezomib enhanced IFN-α induced gene expression.  Together these data 
suggest that bortezomib and IFN-α exert complimentary pro-apoptotic effects on the tumor cell 
and that pre-treatment with bortezomib can sensitize melanoma cells to the direct effects of   
IFN-α.  The safety of this treatment combination is being evaluated in a Phase I clinical trial in 
patients with metastatic melanoma at The Ohio State University (OSU 04105; PI: Carson).   
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Introduction 
 
Interferon-alpha (IFN-α) has been utilized in the treatment of malignant melanoma and 
renal cell carcinoma for the past three decades.  Although its mechanism of action has not been 
fully elucidated, IFN-α possesses potent immunostimulatory properties and direct anti-
proliferative, pro-apoptotic, and anti-angiogenic effects on the tumor cell (1-2).  Specifically, 
IFN-α has been shown to sensitize malignant cells to pro-apoptotic stimuli by increasing the 
expression of death receptors (TRAIL, Fas) and by upregulating the expression of cell cycle 
regulatory proteins (e.g. the CDK inhibitor p21) (3-6).  These observations suggest that IFN-α 
may be an effective means to enhance the pro-apoptotic effects of other targeted therapeutics. 
Treatment of melanoma patients with IFN-α as a single agent yields clinical responses in 
approximately 10-20% of patients (7, 8, 9).  While this response is modest, IFN-α is one of the 
limited options for patients with metastatic melanoma and is the only FDA-approved agent for 
the adjuvant therapy of patients who have undergone tumor excision.  However, chemotherapy 
and high dose cytokine therapy is often poorly tolerated by patients with advanced disease.  
Bortezomib (Velcade®, PS-341) is a novel compound that specifically inhibits the 26S 
proteasome, which plays a critical role in many intracellular events including cell cycle 
progression, transcription factor activation, and apoptosis (10).  The 26S proteasome is 
responsible for ordered, temporal degradation of cyclins and CDK inhibitors (p21 and p27) 
required for cell cycle progression (10, 11).  In the presence of bortezomib, these proteins are 
stabilized, thus arresting the cell cycle and promoting apoptosis. 
Bortezomib possesses in vitro activity against a variety of tumor cell types including 
multiple myeloma, prostate cancer, pancreatic cancer, renal cell carcinoma, and squamous cell 
carcinoma (12-17).  Clinical trials involving treatment with bortezomib demonstrate that it 
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possesses activity in patients with advanced multiple myeloma and has a tolerable toxicity 
profile (15).  It has also demonstrated some clinical activity in other solid tumors, including 
advanced renal cell carcinoma where it produced a partial response in 11% of patients and stable 
disease in 38% of patients (17).  These results suggest that the effects of bortezomib on solid 
tumor cells may be enhanced when used in combination with other pro-apoptotic agents. 
We hypothesized that IFN-α would enhance the anti-tumor effects of bortezomib by 
activating common pro-apoptotic pathways.  We have demonstrated that treatment of malignant 
melanoma cells with the combination of bortezomib and IFN-α synergistically induced apoptotic 
cell death.  Apoptosis induced by this combination was associated with increased cleavage of 
caspase-3 and PARP, slightly increased levels of p21, and decreased levels of Bcl-2.  These data 
demonstrate that the pro-apoptotic effects of bortezomib against malignant melanoma tumors are 
enhanced in the presence of IFN-α and have identified potential molecular targets of this 
treatment combination.    
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Materials and Methods 
 
Cell Lines.  The HT144 and A375 (human) melanoma cell lines were purchased from the 
American Type Cell Culture collection (ATCC, Manassas, VA).  The 1259 MEL and       
18105 MEL human melanoma cell lines were obtained from Dr. Soldano Ferrone (Roswell Park 
Cancer Institute, Buffalo, NY).    
 
 
Reagents.  Murine (mu) IFN-α (specific activity = 3.3 x 106 U/mg) was purchased from Access 
Biochemical (San Diego, CA).  Recombinant human (hu) IFN-α (specific activity = 2 x 108 
IU/mg) was purchased from Schering-Plough, Inc. (Nutley, NJ).  Bortezomib (Velcade®,         
PS-341) was obtained from Millennium Pharmaceuticals Inc. (Cambridge, MA) and 
reconstituted with normal saline (0.9%), to a stock concentration of 1 mg/ml prior to use in all 
assays. 
 
Analysis of Apoptosis with Annexin V/Propidium Iodide (PI) Staining.  The exposure of 
phosphatidyl serine on the cell membrane, a marker of apoptosis, was assessed in tumor cells 
following treatment with PBS, bortezomib (10nM), IFN-α (104 U/mL), or both agents combined 
by flow cytometry using APC-Annexin V and propidium iodide (PI; BD Pharmingen, San          
Diego, CA) (18).  Quantitative data were obtained using a Becton Dickinson FACScalibur 
cytometer (BD Immunocytometry systems, San Jose, CA) and analyzed using WinMDI v. 2.8 
software (created by Joseph Trotter; available at: http://pingu.salk.edu/software.html).  Early 
apoptotic (Annexin V+/PI-), late apoptotic (Annexin V+/PI+), and non-apoptotic (Annexin V-/PI-) 
events were quantified utilizing at least 10,000 events.    
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Immunoblot Analysis.  Cytoplasmic lysates (to measure caspase proteins) were prepared with 
1X CHAPS lysis buffer (Cell Signaling Technology, Inc., Beverly, MA).  Whole cell lysates 
(to measure Bcl-2, p21, PARP) were prepared by harvesting cells into lysis buffer (10% SDS, 
1M Tris-HCl pH 6.8, 0.5M EDTA) containing the following protease inhibitors (1M Sodium 
Flouride, 100mM Sodium Orthovanadate, 100mM Sodium Pyrophosphate).  Loading dye (2X 
SDS-2% 2-beta-mercaptoethanol) was added to samples in a 1:1 ratio and samples were boiled 
for 5 minutes.  Protein in cell extracts was resolved on SDS-polyacrylamide gels and transferred 
via electrophoresis to nitrocellulose membranes.  Membranes were blocked with 5% non-fat 
milk or 5% BSA in TBS-T (100mM Tris-HCl pH 7.5, 0.9% NaCl, 0.1% Tween 20).  
Immunoblots were probed overnight with antibodies (Ab) specific for p21 (Pharmingen, San 
Diego, CA), human Bcl-2, caspase-3, and poly (ADP-ribose) polymerase (PARP) (Cell 
Signaling Technology).  Membranes were next washed twice (5 minutes per wash) with TBS-T 
to rid the nitrocellulose membrane of excess Ab and incubated with appropriate horseradish-
peroxidase-conjugated secondary Ab.  Membranes were washed again with TBS-T and immune 
complexes were detected using the ECL Plus detection kit (Amersham Biosciences, Ayesbury, 
UK).  β-actin, a housekeeping gene, was utilized as a control to confirm equal loading for all 
immunoblots (Sigma).  
 
Real Time PCR.  Total RNA was harvested from cells using TRIzol, a reagent that maintains 
the integrity of RNA while disrupting cell membranes and solubilizing cell components 
(Invitrogen).  Chloroform was then added to samples prior to centrifugation to separate aqueous 
and organic phases.  Following centrifugation, total cellular RNA remained in the aqueous phase 
and was then precipitated using isopropanol.  The resulting RNA pellet was washed with ethanol 
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and resuspended in sterile water.   Reverse transcription was performed using 2 μg of total RNA 
and random hexamers (PerkinElmer, Norwalk, CT) as primers for first-strand synthesis of cDNA 
and the following conditions: 70°C for 2 minutes, 42°C for 60 minutes, and 94°C for 5 minutes.  
We used 2 μL of the resulting cDNA as template to measure the levels of mRNA for IFIT2 by 
real-time RT-PCR with pre-designed primer/probe sets (Assays on Demand; Applied 
Biosystems, Foster City, CA) and 2X TaqMan Universal PCR Master Mix (Applied 
Biosystems).  Pre-designed primer/probe sets for human β-actin (Applied Biosystems), a 
housekeeping gene, were used as an internal control in each reaction well.  Real-time RT-PCR 
reactions were performed in triplicate in capped 96-well optical plates.  The following 
amplification scheme was used: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 
15 seconds, and 60°C for 1 minute.  Real-time RT-PCR data were analyzed using Sequence 
Detector software, version 1.6 (PE Applied Biosystems, Foster City, CA).  
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Results 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α leads to enhanced  
 
apoptotic cell death. 
 
Both bortezomib and IFN-α have been shown to induce tumor cell apoptosis when administered 
as single agents.  It was hypothesized that the pro-apoptotic effects of these two agents would be 
superior to either agent alone when used against melanoma cell lines.  Human and murine 
melanoma cells (B16, MEL 39, HT144) were treated with PBS, bortezomib (10nM), IFN-α   
(104 U/mL), or both agents combined for 48 hours.  Phosphatidyl-serine exposure on the cell 
membrane was then measured by flow cytometry at various time points using fluorescently 
labeled Annexin V in combination with propidium iodide (PI) staining as previously described 
(18).  The combination of bortezomib and IFN-α induced a greater level of apoptosis compared 
to either agent alone in three separate melanoma cell lines (Fig. 1).  For example, treatment of 
the B16 murine melanoma cell line with IFN-α resulted in 6.57% apoptotic cells and bortezomib 
yielded 29.57% apoptotic cells.  However, treatment with both agents combined induced 
apoptosis in 46.81% of cells.  
 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α induces cleavage of  
caspase-3. 
Caspase-3 is a major downstream effector caspase and the cleaved form of this protein is 
partially responsible for the induction of apoptosis (2).  Human melanoma cells were treated with 
PBS, bortezomib (10nM, 20nM), IFN-α (104 U/mL), or both agents combined for 48 hours.  
Immunoblot analysis indicated that treatment of melanoma cells with bortezomib (20nM) or 
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bortezomib (20nM) and IFN-α induced cleavage of caspase-3 at the 48 hour time point (Fig. 2).  
This pattern of caspase activation was reproducible and routinely observed in multiple human 
melanoma cell lines (A375, MEL 1259, MEL 18105; data not shown).   
 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α induces cleavage  
 
of PARP. 
 
The cleavage of poly ADP-ribose polymerase (PARP), an enzyme involved in the surveillance of 
genome integrity and DNA repair, is a valid marker of apoptosis (19).  Human melanoma cells 
were treated with PBS, bortezomib (10nM, 20nM), IFN-α (104 U/mL), or both agents combined 
for 48 hours.  Immunoblot analysis demonstrated that there was an increased level of cleaved 
PARP in melanoma cells that had been treated with the combination as compared to either agent 
alone indicating that a greater level of apoptosis was reached when treated with the combination 
(Fig. 3; arrow).  This pattern of PARP cleavage was reproducible and routinely observed in 
multiple human melanoma cell lines (MEL 1259, MEL 18105). 
 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α leads to decreased 
expression of Bcl-2. 
The Bcl-2 family of mitochondrial proteins are key regulators of apoptosis that promote cell 
survival by stabilizing the mitochondrial membrane (20, 21).  Modulation of these proteins has 
been shown to contribute to the pro-apoptotic effects of bortezomib in Jurkat cells (22).  Human 
melanoma cells were treated for 48 hours with PBS, bortezomib (10nM), IFN-α (104 U/mL), or 
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both agents combined.  Immunoblot analysis demonstrated a significant decrease in the level of 
Bcl-2 protein following treatment of human melanoma cell lines with the combination of 
bortezomib and IFN-α (Fig. 4).  This pattern of decreased Bcl-2 protein was reproducible in 
other human melanoma cell lines treated with bortezomib and IFN-α (A375, HT144). 
 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α leads to increased levels 
of p21.  
Both bortezomib and IFN-α have been shown to induce the accumulation of the cyclin 
dependent kinase inhibitor p21 as single agents in human multiple myeloma and lymphoma cells 
(3, 23).  This molecule is known to promote cell cycle arrest and can serve to sensitize the cell to 
the induction of apoptosis.  To determine whether p21 accumulates prior to the onset of 
apoptosis human melanoma cells were treated for 24 hours with PBS, bortezomib (10nM),    
IFN-α (104 U/mL), or both agents combined.  Enhanced expression of p21 protein was observed 
following treatment with bortezomib alone, while treatment with both agents combined led to 
only a modest enhancement of p21 protein (Fig. 5).  
 
 
Combined treatment of melanoma cell lines with bortezomib and IFN-α induces increased  
 
expression of the IFN-α responsive gene IFIT2. 
 
Since bortezomib and IFN-α induce synergistic apoptosis, we hypothesized that the combined 
treatment of melanoma cells with bortezomib and IFN-α may affect the transcription of IFN-α 
stimulated genes.  Human melanoma cells were treated for 16 hours with bortezomib (10nM, 
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20nM) or PBS and then stimulated with IFN-α (104 U/mL) for 4 hours.  Total cellular RNA was 
isolated and the transcription of the IFN-α-responsive gene IFIT2 was measured by Real Time 
PCR.  Proteasome inhibition resulted in a dose-dependent increase in the expression of IFIT2. 
This effect occurred prior to the onset of cell death (36 – 48 hours).  Similar results were 
observed following an 18-hour co-treatment with bortezomib and IFN-α (Fig.6). 
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Discussion
 We have shown that bortezomib and IFN-α can induce synergistic apoptosis in 
melanoma cell lines.  This apoptosis was associated with cleavage of the downstream effector 
caspase (caspase-3) and PARP.  In addition, we demonstrate that this treatment combination 
resulted in decreased levels of the pro-survival Bcl-2 protein and modest increases in the level of 
the cyclin dependent kinase inhibitor p21.  Finally we have shown that pre-treatment or           
co-treatment with bortezomib leads to enhanced transcription of IFN-α induced genes.  These 
data demonstrate that this treatment combination may be an effective means of inducing 
apoptosis in human melanoma cells or sensitizing cells to the direct actions of IFN-α. 
Apoptosis or programmed cell death consists of the ordered disassembly of the cell from 
within as opposed to necrosis or accidental cell death.  Apoptosis may be induced through the 
extrinsic pathway (activation of cell surface death receptors) or the intrinsic pathway (alterations 
in the integrity of the mitochondrial membrane that induce the release of cytochrome c) (24).  
These pathways converge at the level of the effector caspases (caspase-3, -6, and –7) (24).  Once 
activated, these effector caspases cleave cytoskeletal and nuclear proteins such as poly         
ADP-ribose polymerase (PARP) thereby initiating cellular disassembly (24).  We have 
demonstrated that both caspase-3 and PARP are cleaved in response to treatment of melanoma 
cells with bortezomib and IFN-α combined, supporting the premise that cell death occurs in a 
manner consistent with apoptosis.   
The Bcl-2 family of proteins function as key regulators of apoptosis that promote cell 
survival by controlling mitochondrial membrane permeability and the release of cytochrome c 
into the cytoplasm (20-21).  The Bcl-2 protein is an anti-apoptotic member of this family that 
appears to antagonize the actions of the pro-apoptotic counterparts in this family.  Although the 
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exact mechanism remains unknown, the Bcl-2 protein has been shown to inhibit the pro-
apoptotic Bcl-2 family protein, Bak, and to regulate cytochrome c release from the mitochondria 
(22, 25).  Interestingly, the Bcl-2 family of proteins has been shown to play a role in the 
resistance of Jurkat cells to apoptosis (26).  In the present study, decreased levels of Bcl-2 were 
observed following the treatment of human melanoma cell lines with bortezomib, and this effect 
was markedly enhanced by the combination of bortezomib and IFN-α.  Future studies will define 
the role of Bcl-2 in promoting the pro-apoptotic effects of this treatment combination.  
The cyclin dependent kinase inhibitor, p21, is involved in regulating the cell cycle (3, 
23).  IFN-α has been shown to increase levels of p21 which in turn leads to cell cycle arrest (23).  
The ordered degradation of CDK inhibitors is required for cell cycle progression in normal and 
malignant cells.  Following treatment with bortezomib, the proteasome is inhibited thereby 
disrupting the necessary degradation of p21 and leading to cell cycle arrest.  There was a modest 
increase observed in the level of p21 protein when melanoma cells were treated with the 
combination of bortezomib and IFN-α as compared to either agent alone.      
In addition to its immune-enhancing effects, IFN-α is also known to act on the tumor cell 
to decrease cell proliferation and promote apoptosis (2).  These processes are mediated in part 
through the transcription and translation of IFN-α stimulated genes.  In the present study, we 
have shown that both pre-treatment with bortezomib and co-treatment with bortezomib and  
IFN-α increases the expression of IFN-α-stimulated genes.  These data suggest that inhibition of 
the proteasome via treatment with bortezomib may enhance the sensitivity of melanoma cells to 
the direct effects of IFN-α.  IFN-α is one of the few treatment options available to those afflicted 
with malignant melanoma and these data show that there may be ways to enhance the activity of 
this compound via proteasome inhibition with bortezomib. 
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We have demonstrated that bortezomib and IFN-α can effectively induce apoptosis in 
human melanoma cell lines.  This treatment combination is currently being tested in a Phase I 
Clinical Trial at The Ohio State University Medical Center (OSU 04105; PI: W.E. Carson).  
Recently published research indicates that this drug combination may also be used to combat 
bladder cancer as well (27).  Further research is necessary to fully elucidate the mechanism by 
which bortezomib and IFN-α work together to induce apoptosis in tumor cells.  Establishing this 
mechanism is of particular importance since it may provide novel targets for cancer prevention 
and therapy. 
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Figure Legends 
 
 
Figure 1: Combined treatment of melanoma cell lines with bortezomib and IFN-α induces 
apoptotic cell death.  (A-C) Apoptosis was measured by flow cytometry following a 48 hour 
treatment with PBS, bortezomib (10nM), IFN-α (104 U/mL), or both agents combined.  Data in 
each dot plot were derived from a minimum of 10,000 events.  Annexin-V staining is depicted on 
the x-axis while PI staining is shown on the y-axis.  The percentage of Annexin-V positive cells 
is included on each dot plot for comparison.  
 
Figure 2: Combined treatment of melanoma cell lines with bortezomib and IFN-α induces 
cleavage of caspase-3.  Human melanoma cells (1259 MEL) were treated for 48 hours with PBS, 
bortezomib (10-20nM), IFN-α (104 U/mL), or both agents combined.  Cell lysates were analyzed 
by immunoblot analysis for caspase-3 protein or its cleaved forms (arrow).  Membranes were 
also probed with an anti-β-actin Ab to control for equal loading.  Similar results were observed 
in the A375, 1259 MEL and 18105 MEL human melanoma cell lines.  B = Bortezomib. 
 
Figure 3: Combined treatment of melanoma cell lines with bortezomib and IFN-α induces 
cleavage of PARP.  Human melanoma cell lines (1259 MEL and 18105 MEL) were treated for 
48 hours with PBS, bortezomib (10-20nM), IFN-α (104 U/mL), or both agents combined.  Cell 
lysates were analyzed by immunoblot analysis for PARP or its cleaved form (arrows).  
Membranes were also probed with an anti-β-actin Ab to control for equal loading.  Similar 
results were observed in A375 human melanoma cell line.  B = Bortezomib. 
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Figure 4: Combined treatment of melanoma cell lines with bortezomib and IFN-α leads to 
decreased levels of Bcl-2.  Immunoblot analysis of Bcl-2, expression in human A375 melanoma 
cells following treatment with PBS, IFN-α (104 U/mL), bortezomib (10nM) or both agents 
combined for 48 hours.  Membranes were also probed with an anti-β-actin Ab to control for 
equal loading.  Similar results were also observed in HT144 melanoma cells (data not shown).  
 
Figure 5: Combined treatment of melanoma cell lines with bortezomib alone or bortezomib and 
 IFN-α leads to increased p21.  Immunoblot analysis of p21 expression in human 1259 MEL 
melanoma cells following treatment with PBS, IFN-α, bortezomib (10nM; B) or both agents 
combined for 48 hours.  Membranes were also probed with an anti-β-actin Ab to control for 
equal loading.  Similar results were also observed in HT144 and A375 human melanoma cells 
(data not shown).  
 
Figure 6: Combined treatment of melanoma cell lines with bortezomib and IFN-α induces 
increased expression of the IFN-α responsive gene IFIT2.  A) Human melanoma cells were 
treated with PBS, IFN-α (104 U/mL), bortezomib (10-20nM), or both agents combined.  RNA 
was isolated, converted to cDNA via RT-PCR, and then analyzed using Real-Time PCR.  All 
gene expression levels were normalized to β-actin expression, and expressed as fold-increase 
versus PBS treated cells.  Similar results were observed following A) an 18 hour pre-treatment 
with bortezomib followed by a 4 hour stimulation with IFN-α in the A375 cell line, B) an 18 
hour co-treatment with bortezomib and IFN-α in the A375 cell line, and C) a 24 hour co-
treatment with bortezomib and IFN-α in the 18105 MEL cell line. 
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